Nov 29, 2023 01:40PM
Aug 8, 2023 08:00AM
Jul 28, 2023 07:30AM
Jul 26, 2023 07:30AM
Jul 21, 2023 09:10AM
Jul 21, 2023 09:09AM
Jul 18, 2023 07:40AM Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
Jul 13, 2023 08:00AM
Jul 10, 2023 07:30AM
Jul 6, 2023 08:42AM
Jun 23, 2023 08:00AM
Jun 16, 2023 08:00AM
May 30, 2023 08:00AM
May 5, 2023 07:30AM Incannex enters a lease for first psychedelic-assisted psychotherapy clinic
May 2, 2023 07:30AM
Apr 14, 2023 07:30AM
Mar 16, 2023 08:51AM
Mar 15, 2023 07:30AM
Mar 3, 2023 07:30AM
Feb 28, 2023 07:25AM
Jan 18, 2023 08:00AM Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety
Dec 6, 2022 08:00AM
Nov 29, 2022 08:00AM
Nov 28, 2022 08:00AM
Nov 17, 2022 08:00AM
Oct 28, 2022 08:00AM
Oct 13, 2022 08:00AM
Oct 11, 2022 08:00AM Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
Sep 8, 2022 09:15AM
Aug 17, 2022 08:00AM
Aug 2, 2022 07:55AM
Jul 27, 2022 07:55AM
Jul 21, 2022 07:55AM
Jun 27, 2022 06:55AM
Jun 3, 2022 07:55AM Incannex (IXHL) announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
Jun 3, 2022 07:55AM
May 17, 2022 07:55AM
May 12, 2022 07:55AM
May 10, 2022 07:55AM
Apr 28, 2022 07:55AM
Apr 28, 2022 07:25AM
Mar 10, 2022 07:59AM Incannex Healthcare (IXHL) observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies
Mar 10, 2022 07:55AM
Mar 3, 2022 07:55AM
Feb 28, 2022 07:55AM
Dec 1, 2020 09:58AM

328,513 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All